Bernstein Karen 4

What Happened

• Karen Bernstein, a director of Ovid Therapeutics, was granted a derivative award of 65,000 shares on 2026-02-26. The Form 4 shows an acquisition value of $0.00, indicating a grant/award (not a cash purchase or open-market sale).

Key Details

• Transaction date: 2026-02-26; reported on Form 4 filed 2026-03-02 (timely filing).
• Transaction type/code: A (Grant/Award/Other Acquisition); amount: 65,000 derivative shares; price reported: $0.00.
• Vesting/footnote: The award will vest in full on February 26, 2027, subject to Bernstein’s continuous service through that date (Footnote F1).
• Shares owned after transaction: Not specified in the filing.
• No 10b5-1 plan, tax-withholding, or sale was reported in this filing.

Context

• This was a time-based equity award (derivative grant) for a director — not an open-market purchase or sale. Such grants are common as compensation for board service; the award does not represent immediately tradable shares until vested (and possibly exercised, if options).